Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022ACA005 | Other Grant/Funding Number | Major science and technology project of Hubei Province, China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Headache is one of the most common chief complaints in clinical practice, with a high global prevalence rate. It may originate from a primary headache disorder or manifest as a clinical symptom of various diseases due to the complexity of its triggers, specific types, diagnosis, and treatment which present significant challenges. As people's life pace continues to accelerate and psychological and physiological pressures increase, many patients experience headache symptoms, leading to a growing number of patients seeking treatment in neurology departments. The increasing incidence of headache conditions has resulted in a decline in patients' quality of life.
Therefore, this research is part of Hubei Province's major project "Discovery and Functional Research of Major Disease Targets Based on Genetic Big Data." The study aims to establish a clinical cohort and develop a precise diagnosis and treatment system for headaches. This system will collect the history of headache sufferers, record the real-world treatment data, and incorporate sample banks, multi-dimensional databases, pre-clinical drug evaluation platforms, and clinical efficacy precise dynamic monitoring models through immunotherapy and other cutting-edge biotechnologies, multi-omics detection technologies, and big data bioinformatics analysis technologies.
The system will provide scientists and clinicians with auxiliary diagnostic and treatment decision support, offer reliable screening targets for early headache diagnosis and drug development companies, accelerate the latest headache diagnosis and targeted treatment, and achieve breakthrough advances in headache prevention and cure.
This research is a multi-center, prospective observational study focusing on headache patients, initiated by Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology (HUST). The study encompasses several key components:
Initial data collection includes:
Follow-up Protocol:
Duration: 10 years Follow-up intervals: face-to-face interviews during the first three months and telephone follow-ups by years
Monitoring parameters:
Technical Framework:
Database Development:
Establishment of several integrated databases:
Clinical database (epidemiological data, imaging, and EEG assessments) Biological sample repository Multi-omics bioinformatics database
Advanced Technical Applications:
Implementation of cutting-edge biotechnologies:
Immunotherapy approaches Multi-omics detection technologies Big data bioinformatics analysis
Analytical Components:
Development of machine learning algorithms Drug target evaluation systems Clinical efficacy monitoring models Outcome prediction models
Research Objectives Implementation:
Construction of molecular interaction networks related to headache Development of AI-based drug target assessment tools Establishment of standardized follow-up evaluation systems Validation of potential drug targets Creation of a comprehensive data-sharing platform
Expected Outcomes:
Enhanced understanding of headache pathogenesis Improved diagnostic capabilities Identification of novel therapeutic targets Development of personalized treatment approaches Establishment of a standardized evaluation system for clinical outcomes This detailed research framework aims to create a comprehensive precision medicine system for headache diagnosis and treatment, ultimately contributing to breakthrough advances in headache prevention and treatment strategies.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Headache patients undergoing routine treatment | Fifty thousand headache patients from several headache centers in China will be recorded to establish a headache database. Data collection includes epidemiological information, clinical data, neuroimaging, questionnaires, and real-world treatments. A cohort of 1,500 headache patients at Tongji Hospital's Neurology Department will receive blood and multi-model imaging collections. The patients will receive monthly interviews and undergo annual telephone follow-ups for 10 years. This cohort will contribute to establishing an integrated database system combining clinical, biological, and multi-omics data for precision medicine development in headache treatment. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Development of integrated precision diagnosis and treatment system for headache | Establishment and validation of a comprehensive system combining: Clinical database and biological repository real-world treatment and efficiency Multimodal neuroimaging biomarkers (MRI, EEG) Multi-omics data analysis to guide precise diagnosis and personalized treatment decisions. | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Brain network characterization and biomarker identification | Structural and functional connectivity patterns from multimodal MRI HD-EEG spectral power and connectivity measures Integration with clinical and molecular data | Baseline and annual follow-up for 5 years |
| Clinical efficacy of treatment approaches |
| Measure | Description | Time Frame |
|---|---|---|
| Longitudinal changes in brain structure and function | Tracking neuroimaging biomarkers and their relationship to clinical outcomes. | Annual assessment for 5 years |
| Database quality and integration | Evaluation of data completeness and successful integration of clinical, imaging, and molecular data. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Participants will be recruited from several headache centers around China including Tongji Hospital. The study population includes patients aged 6-70 years diagnosed with headache according to ICHD-3 (2018) criteria. Eligible participants must be mentally competent to provide detailed headache history and demonstrate willingness to comply with follow-up assessments. Patients with complex headache etiology (≥3 distinct causal factors), severe systemic diseases, limited life expectancy (<10 years), or significant cognitive/psychiatric impairments affecting study participation will be excluded. A total of 1,500 participants meeting these criteria will be enrolled and followed for 5 years.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wensheng Qu Professor, DM PhD | Contact | +8618971622660 | wsqu@tjh.tjmu.edu.cn | |
| Han Zhang Dr, MD PhD | Contact | +8618627023031 | 523852566@qq.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | Wuhan | Hubei | 430030 | China |
Individual participant data that underlie the results reported in this study, after de-identification (text, tables, figures, and appendices), will be available for academic purposes. The study protocol and statistical analysis plan will also be available.
Data will be available beginning 9 months and ending 36 months following article publication.
Researchers who provide a methodologically sound proposal and sign a data access agreement.
Not provided
Not provided
| ID | Term |
|---|---|
| D006261 | Headache |
| ID | Term |
|---|---|
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood
Treatment effectiveness assessment through standardized outcomes Correlation between imaging biomarkers and clinical improvement Predictive models for treatment response |
| Baseline and annual follow-up for 5 years |
| Novel therapeutic target identification | Discovery and validation of potential drug targets through: Multi-omics analysis Neuroimaging biomarkers Machine learning approaches | 5 years |
| Annual assessment for 5 years |
| Adverse events and follow-up compliance | Monitoring of treatment-related adverse events and follow-up completion rates. | Throughout study period, up to 5 years |